Overcoming limitations of existing antibody-drug conjugates (ADC) Addressing tumor heterogeneity and drug resistance Combining PARP inhibitor-targeted anticancer drugs with site-selective conjugation technology Aiming to develop next-generation ADC anticancer drugs for multiple cancer types
Han Tae-dong, CEO of Aptis, expressed, "We hope that the synergy created by combining Aptis's proprietary ADC-related technologies and platforms with Idience's anticancer drug pipeline will become a turning point in opening a new chapter in the development of next-generation dual payload ADCs."
Kim Min-beom
AI-translated with ChatGPT. Provided as is; original Korean text prevails.
ⓒ dongA.com. All rights reserved. Reproduction, redistribution, or use for AI training prohibited.
